Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Chengdu Kanghong's KH815 enters human testing this month.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
A biliary tract cancer trial hits on response rate, but survival data will be key.
AACR approaches, along with ASCO abstract titles.
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
